Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration ...

The US government has cancelled a $590 million Moderna deal for a bird flu vaccine over safety and ethical concerns about ...

HHS has notified Moderna that it is canceling a nearly $600 million contract for vaccines for flu strains that could trigger ...

Silexion Therapeutics Corp (NASDAQ:SLXN) has announced breakthrough preclinical results for its next-generation RNA ...

“While the termination of funding from HHS adds uncertainty, we are pleased by the robust immune response and safety profile ...

Arrowhead Pharmaceuticals, Inc.'s deal with Sarepta expands its pipeline, but limited plozasiran market and competition ...

The latest imaging method from the Broad Institute uncovers structural disruptions in the nucleus associated with progeria at super-resolution.

Successful trial results in the next few years could save thousands of lives and generate billions in new annual revenue for ...

Intellia Therapeutics shares fell 25% amid safety concerns in Phase 3 trials. Check out if today's selloff in NTLA stock is a ...

At some point, RNA must have replicated itself before the evolutionary arrival of DNA and proteins, and now we might know how ...

Researchers at the Max Planck Institute for Evolutionary Anthropology have addressed a longstanding challenge in CRISPR ...

One of the longstanding challenges in chemical biology has been finding ways to directly observe biological processes at work ...